Table 1.
Association between HPV and TERTp mutation and patient characteristics
| Parameter | Total | HPV | TERTp | ||||
|---|---|---|---|---|---|---|---|
| Positive | Negative | P | Mutated | Wildtype | P | ||
| N = 80 (%) | n = 64 (80.0%) | n = 16 (20.0%) | n = 6 (7.5%) | n = 74 (92.5%) | |||
| Sex | 1.000 | 1.000 | |||||
| Male | 70 (87.5) | 56 (87.5) | 14 (87.5) | 6 (100) | 64 (86.5) | ||
| Female | 10 (12.5) | 8 (12.5) | 2 (12.5) | 0 (0) | 10 (13.5) | ||
| Age (year) | 0.010* | 1.000 | |||||
| ≤ 60 | 52 (65.0) | 46 (71.9) | 6 (37.5) | 4 (66.7) | 48 (64.9) | ||
| > 60 | 28 (35.0) | 18 (28.1) | 10 (62.5) | 2 (33.3) | 26 (35.1) | ||
| Smoking | 0.263 | 0.392 | |||||
| Light | 33 (41.3) | 32 (50.0) | 5 (31.2) | 1 (16.7) | 32 (43.2) | ||
| Heavy | 47 (58.7) | 32 (50.0) | 11 (68.8) | 5 (83.3) | 42 (56.8) | ||
| Alcohol | 0.021* | 0.667 | |||||
| Light | 50 (62.5) | 44 (68.8) | 6 (37.5) | 3 (50.0) | 47 (63.5) | ||
| Heavy | 30 (37.5) | 20 (31.2) | 10 (62.5) | 3 (50.0) | 27 (36.5) | ||
| Tumor location | 0.173 | 0.651 | |||||
| Right side | 47 (58.7) | 40 (62.5) | 7 (43.8) | 3 (50.0) | 44 (59.5) | ||
| Left side | 33 (41.3) | 24 (37.5) | 9 (56.2) | 3 (50.0) | 30 (40.5) | ||
| pT category | 0.088 | 0.556 | |||||
| T1-T2 | 49 (61.3) | 36 (56.3) | 13 (81.3) | 3 (50.0) | 46 (62.2) | ||
| T3-T4 | 31 (38.7) | 28 (43.7) | 3 (18.7) | 3 (50.0) | 28 (37.8) | ||
| pNodal status | < 0.001* | 0.333 | |||||
| N0 | 17 (21.3) | 8 (12.5) | 9 (56.2) | 0 (0) | 17 (23.0) | ||
| N1–3 | 63 (78.7) | 56 (87.5) | 7 (43.8) | 6 (100) | 57 (77.0) | ||
| pAJCC stage (8th) | 0.020* | 0.624 | |||||
| I–III | 60 (75.0) | 52 (81.2) | 8 (50.0) | 4 (66.7) | 56 (75.7) | ||
| IV | 20 (25.0) | 12 (18.8) | 8 (50.0) | 2 (33.3) | 18 (24.3) | ||
| HPV status | – | 1.000 | |||||
| Positive | 64 (80.0) | – | – | 5 (83.3) | 59 (79.7) | ||
| Negative | 16 (20.0) | – | – | 1 (16.7) | 15 (20.3) | ||
| BOT invasion | 0.263 | 0.407 | |||||
| Present | 43 (53.8) | 32 (50.0) | 5 (31.2) | 4 (66.7) | 33 (44.6) | ||
| Absent | 37 (46.2) | 32 (50.0) | 11 (68.8) | 2 (33.3) | 41 (55.4) | ||
| Soft palate invasion | 0.154 | 0.423 | |||||
| Present | 28 (35.0) | 25 (39.1) | 3 (18.7) | 3 (50.0) | 25 (33.8) | ||
| Absent | 52 (65.0) | 39 (60.9) | 13 (81.3) | 3 (50.0) | 49 (66.2) | ||
| Ipsilateral LN meta | 0.004* | 1.000 | |||||
| Present | 58 (72.5) | 51 (79.7) | 7 (43.8) | 5 (83.3) | 53 (71.6) | ||
| Absent | 22 (27.5) | 13 (20.3) | 9 (56.2) | 1 (16.7) | 21 (28.4) | ||
| Contralateral LN meta | 1.000 | 1.000 | |||||
| Present | 12 (15.0) | 10 (15.6) | 2 (12.5) | 1 (16.7) | 11 (14.9) | ||
| Absent | 68 (85.0) | 54 (84.4) | 14 (87.5) | 5 (83.3) | 63 (85.1) | ||
| ENE | 0.485 | 0.409 | |||||
| Present | 51 (63.8) | 42 (65.6) | 9 (56.2) | 5 (83.3) | 46 (62.2) | ||
| Absent | 29 (36.2) | 22 (34.4) | 7 (43.8) | 1 (16.7) | 28 (37.8) | ||
HPV human papillomavirus, p pathologic, LN lymph node, BOT base of tongue, AJCC American Joint Committee on Cancer, ENE extranodal extension
*Statistically significant, P < 0.05